查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401841

2030 年迷幻药市场预测：按产品类型、药物类型、应用、最终用户和地区分類的全球分析

Psychedelic Market Forecasts to 2030 - Global Analysis By Product, Drug Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球迷幻药物市场规模将达到 8 亿美元，预计 2030 年将达到 22.1 亿美元，预测期内复合年增长率为 15.4%。

致幻剂，也称为致幻剂，是一种改变知觉、情绪和各种认知过程的物质。致幻剂通常会引起意识的深刻变化，导致思想、情绪和感觉的变化。几个世纪以来，致幻剂一直在各种文化中用于宗教、精神和萨满目的。提高创造力、注意力和情绪。

负责全球公共卫生的联合国专门机构世界卫生组织的报告估计，每年约有 5% 的美国人患有创伤后压力症候群 (PTSD)。

治疗的可能性正在被认识到

全球范围内心理健康问题的增加和现有治疗方法的不足促使人们寻找新的有效的治疗性介入。此类研究的积极成果和有希望的结果将有助于改变人们对迷幻药的看法，从滥用物质转变为潜在的治疗药物，从而增加研究人员、医疗保健专业人员和製药行业的兴趣。此外，人们对迷幻药潜在治疗益处的认识和教育的提高导致了社会态度的变化，推动了市场的成长。

缺乏标准化

临床试验缺乏标准化方案导致试验设计有差异，且难以比较和解释不同试验的结果。为了安全有效地使用迷幻物质，确定适当的给药和给药方法非常重要。如果没有标准化的指南，最佳给药尚不清楚，可能会导致安全问题和次优的治疗结果。这一因素阻碍了市场的拓展。

新治疗模式的兴起

人们对裸盖菇素和摇头丸等致幻物质的治疗潜力的兴趣和研究不断增长，引发了大量的临床试验。这些临床试验的正面结果引起了人们对迷幻药辅助性治疗的关注和支持。社会对心理健康态度的改变以及对传统精神科治疗局限性的认识导致了人们对迷幻药的看法发生了转变。此外，倡导团体和患者的证词在提高人们对心理治疗潜在益处的认识方面发挥着重要作用。这些因素的结合正在创造一个有利于迷幻药物市场成长的环境。

医学功效与研究挑战

主要研究挑战之一是给药和给药技术的标准化。在致幻剂/药物可以广泛用作治疗或药物之前，它们必须在临床试验中通过严格的安全性和有效性测试。如果精神药物研究缺乏科学严谨性或被视为不确定，公众的不信任和怀疑可能会增加。除非有足够的证据证明治疗效果，否则保险公司可能不愿意支付迷幻治疗费用。它还减少了患者可用的替代治疗的多样性。市场需求受到这些变数的阻碍。

COVID-19 的影响

COVID-19 的爆发对迷幻药市场产生了负面影响。这种流行病阻碍了致幻药物的研究和临床试验的进展。封锁、旅行限制和麵对面会议的限制导致研究和临床试验的延误。金融市场经历了早期的起伏，改变了包括迷幻剂在内的各个阶段的投资者情绪。此外，知识的增加和对心理健康态度的改变为后疫情时代迷幻治疗的接受和采用创造了有利的环境。

裸盖菇素预计将在预测期内成为最大的细分市场

裸盖菇素领域预计将出现良好的成长。裸盖菇素主要因其致幻作用而闻名，可引起知觉、感官体验和意识的变化。人们认为它透过影响与情绪调节和情绪处理相关的神经途径来发挥作用。一些研究显示出有希望的结果，裸盖菇素辅助治疗可显着减轻忧郁症状并改善情绪健康。减少焦虑、增加创造力、缓解头痛和增强正念等好处正在推动这一领域的需求。

恐慌症产业预计在预测期内复合年增长率最高

由于其综合治疗和情绪处理的增强，预计恐慌症领域在预测期内将出现最高的复合年增长率。迷幻体验通常伴随着高度的内省和正念感。这种增强的意识可以帮助个人面对和处理他们的恐惧，使他们更能接受自己的情绪和经验。许多迷幻药，包括裸盖菇素和LSD，主要与大脑中的血清素受体相互作用。这可以暂时改变个人体验和处理恐惧的方式，可能有助于打破恐慌的循环。

占有率最大的地区

预计亚太地区在预测期内将占据最大的市场占有率。亚太地区对迷幻药物研发的兴趣日益浓厚，特别是在心理健康领域。此外，人们对这一领域的迷幻投资和新兴企业越来越感兴趣。印度在市场占有率和收入方面领先迷幻药物产业。随着该地区越来越多地接受这些治疗忧郁症的药物，而快速的研发刺激了该行业，这一优势预计将持续下去。

复合年增长率最高的地区：

由于研究试验的扩大和法规环境的变化，预计北美在预测期内将出现最高的复合年增长率。在北美开展业务的主要企业包括辉瑞 (Pfizer)、Theron Pharmaceuticals、Cybin、Jazz Pharmaceuticals 和 Pharmacer Holdings。在北美，忧郁症精神疾病的盛行率正在增加。为了教育加拿大人了解精神疾病的现实，加拿大政府每週都会举办一次精神疾病宣导宣传活动。由于精神疾病的增加和意识计划的加强，预计北美将进一步增长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球迷幻药市场：按产品

  • 麦角酸二乙酰胺 (LSD)
  • 3,4-亚甲基二氧基甲基安非他命（摇头丸）
  • 苯环己哌啶
  • γ-羟基丁酸 (GHB)
  • 乙胺
  • 死藤水
  • 丹参
  • 裸盖菇素

第六章全球迷幻药市场：依药物类型

  • 注射致幻剂
  • 口服致幻剂
  • 经皮致幻剂
  • 直肠致幻剂
  • 鼻致幻剂

第七章全球致幻剂市场：依应用分类

  • 重度忧郁症
  • 抗治疗性忧郁症
  • 恐慌症
  • 创伤后压力症候群
  • 鸦片上瘾
  • 发作性睡病
  • 其他用途

第八章全球迷幻药市场：依最终用户分类

  • 专科诊所
  • 医院
  • 居家照护
  • 其他最终用户

第九章全球迷幻药市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Johnson & Johnson（J&J）
  • Enveric Biosciences
  • Ceruvia Lifesciences
  • Apex Labs
  • Numinus Wellness Inc
  • Jazz Pharmaceuticals
  • Cybin Inc
  • Revive Therapeutics
  • Psychedelic Water
  • PharmaTher Holdings Limited
  • MindMed
  • Compass Pathways
  • Field Trip Health
  • ATAI Life Sciences
  • Hikma Pharmaceuticals PLC
  • Verrian
  • Celon Pharma SA
  • NRX Pharmaceuticals
  • Rose Hill Company
  • Psycheceutical Bioscience Inc
Product Code: SMRC24361

According to Stratistics MRC, the Global Psychedelic Market is accounted for $0.8 billion in 2023 and is expected to reach $2.21 billion by 2030 growing at a CAGR of 15.4% during the forecast period. Psychedelics, also known as hallucinogens, are a class of substances that alter perception, mood, and various cognitive processes. They often induce profound changes in consciousness, leading to altered thoughts, feelings, and sensory perceptions. Psychedelics have been used for centuries in various cultures for religious, spiritual, or shamanic purposes. It enhances creativity, focus, and mood.

According to the report by World Health Organization, a specialized agency of the United Nations responsible for international public health, it was estimated that, approximately 5% of Americans suffer from PTSD each year.

Market Dynamics:

Driver:

Growing acceptance of the therapeutic potential

The global increase in mental health issues and the inadequacy of existing treatments have led to a search for novel and effective therapeutic interventions. Positive outcomes and promising results from these studies have helped change the perception of psychedelics from substances of abuse to potential therapeutic agents, stimulating interest from researchers, healthcare professionals, and the pharmaceutical industry. Additionally, increased awareness and education about the potential therapeutic benefits of psychedelics have contributed to changing societal attitudes which is thereby fuelling the market growth.

Restraint:

Lack of standardization

Lack of standardized protocols for clinical trials can lead to variability in study designs, making it challenging to compare and interpret results across different trials. Determining appropriate dosages and administration methods for psychedelic substances is critical for their safe and effective use. Without standardized guidelines, there may be a lack of clarity on optimal dosages, leading to potential safety concerns or suboptimal therapeutic outcomes. This element is hindering the market from expansion.

Opportunity:

Rise in new treatment paradigms

Increased scientific interest and research in the therapeutic potential of psychedelic substances, such as psilocybin and MDMA, have led to numerous clinical trials. Positive results from these trials have garnered attention and support for psychedelic-assisted therapies. Evolving societal attitudes towards mental health and a growing acknowledgment of the limitations of traditional psychiatric treatments have shifted perceptions of psychedelics. Also, advocacy groups and patient testimonials have played a crucial role in raising awareness about the potential benefits of psychedelic-assisted therapies. The convergence of these factors has created a conducive environment for the growth of the psychedelic market

Threat:

Medical efficacy & research challenges

One of the primary research problems is to standardize dose and delivery techniques. Before psychedelic drugs are extensively utilised for therapeutic or medicinal purposes, they need to pass stringent safety and effectiveness testing in clinical studies. Public mistrust and scepticism may increase if studies on psychedelics are seen as missing scientific rigour or being inconclusive. Insurance companies could be hesitant to pay for psychedelic therapies if there isn't enough proof of their therapeutic benefits. It also reduces the variety of therapeutic alternatives that patients can choose from. The market demand is hampered by these variables.

COVID-19 Impact

The COVID-19 pandemic had negatively impacted the psychedelic market. The epidemic hampered the advancement of psychedelic research investigations and clinical trials. Lockdowns, travel restrictions, and limits on face-to-face meetings caused delays to research efforts and trials. Financial markets experienced volatility during the early phases, leading to changes in investor sentiment across various sectors, including psychedelics. In addition, a more suitable climate for the acceptance and incorporation of psychedelic treatments in the post-pandemic age was created by growing knowledge and shifting attitudes towards mental health.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is estimated to have a lucrative growth. Psilocybin is primarily known for its psychedelic effects, inducing altered perceptions, sensory experiences, and changes in consciousness. It is believed to work by influencing neural pathways associated with mood regulation and emotional processing. Some studies have shown promising results, with psilocybin-assisted therapy leading to significant reductions in depressive symptoms and improved emotional well-being. Its benefits namely anxiety reduction, enhancing creativity, headache relief and heightened mindfulness fuels the segment demand.

The panic disorders segment is expected to have the highest CAGR during the forecast period

The panic disorders segment is anticipated to witness the highest CAGR growth during the forecast period, due to its integrated therapies and enhanced emotional processing. The psychedelic experience often involves a heightened sense of introspection and mindfulness. This increased awareness may help individuals confront and process their fears, fostering a greater acceptance of emotions and experiences. Many psychedelics, including psilocybin and LSD, primarily interact with serotonin receptors in the brain. This can lead to a temporary shift in the way individuals experience and process fear, potentially helping to break the cycle of panic.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. There is a growing interest in psychedelic research and development in the Asia-Pacific region, especially in the area of mental health. Additionally, there has been an increase in interest in psychedelic investments and start-ups in the area. In terms of market share and income, India leads the psychedelic drug industry. This dominance is expected to persist as the region's acceptance of these medications for the treatment of depression grows and the industry is being stimulated by rapid research development.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to expanding research trials and shifting regulatory environment. It is home for major key players such as Pfizer Inc, Celon Pharmaceuticals, Cybin Corp, Jazz Pharmaceuticals, and PharmaTher Holdings. There is a rise in the prevalence of mental illnesses like depression in North America. To further inform Canadians on the realities of mental illness, the government of Canada also runs a weekly campaign to raise awareness of the condition. North America is further anticipated to witness growth with rising mental illness and growing awareness programs.

Key players in the market:

Some of the key players profiled in the Psychedelic Market include Johnson & Johnson (J&J), Enveric Biosciences, Ceruvia Lifesciences, Apex Labs, Numinus Wellness Inc, Jazz Pharmaceuticals, Cybin Inc, Revive Therapeutics, Psychedelic Water, PharmaTher Holdings Limited, MindMed, Compass Pathways, Field Trip Health, ATAI Life Sciences, Hikma Pharmaceuticals PLC, Verrian, Celon Pharma SA, NRX Pharmaceuticals, Rose Hill Company and Psycheceutical Bioscience Inc.

Key Developments:

In November 2023, Psycheceutical Bioscience Inc announced the launch of a community crowd funding campaign on Wefunder. The campaign is currently open to all investors, and serves as the next step in Psycheceutical's mission to revolutionize mental health treatment by bringing safe, effective, and accessible psychedelic therapies to patients worldwide using precise drug delivery technologies.

In October 2023, The viral brand Psychedelic Water has launched a new product line: Psychedelic Good Mood Mix. This new product takes Psychedelic Water's award-winning kava-based alcohol alternative and brings it to a new format: a powder drink mix. Psychedelic Good Mood Mix's powder format is lightweight, making it highly portable.

In August 2023, Rose Hill Company, the leading cultivator, supplier and exporter of premium psilocybin products and biomass in Jamaica, celebrates the premier of their psychedelic wellness program, ONE Retreats, and the launch of their newest psilocybin product- the PATOO gummy. These milestones strengthen Rose Hill's total business and prime the Company for U.S. expansion.

Products Covered:

  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Etamine
  • Ayahuasca
  • Salvia
  • Psilocybin

Drug Types Covered:

  • Injectable Psychedelic Drugs
  • Oral Psychedelic Drugs
  • Transdermal Psychedelic Drugs
  • Rectal Psychedelic Drugs
  • Nasal Psychedelic Drugs

Applications Covered:

  • Major Depressive Disorder
  • Resistant Depression
  • Panic Disorder
  • Post-Traumatic Stress Disorder
  • Opiate Addiction
  • Narcolepsy
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Hospitals
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Psychedelic Market, By Product

  • 5.1 Introduction
  • 5.2 Lysergic Acid Diethylamide (LSD)
  • 5.3 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • 5.4 Phencyclidine
  • 5.5 Gamma Hydroxybutyric Acid (GHB)
  • 5.6 Etamine
  • 5.7 Ayahuasca
  • 5.8 Salvia
  • 5.9 Psilocybin

6 Global Psychedelic Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Injectable Psychedelic Drugs
  • 6.3 Oral Psychedelic Drugs
  • 6.4 Transdermal Psychedelic Drugs
  • 6.5 Rectal Psychedelic Drugs
  • 6.6 Nasal Psychedelic Drugs

7 Global Psychedelic Market, By Application

  • 7.1 Introduction
  • 7.2 Major Depressive Disorder
  • 7.3 Resistant Depression
  • 7.4 Panic Disorder
  • 7.5 Post-Traumatic Stress Disorder
  • 7.6 Opiate Addiction
  • 7.7 Narcolepsy
  • 7.8 Other Applications

8 Global Psychedelic Market, By End User

  • 8.1 Introduction
  • 8.2 Specialty Clinics
  • 8.3 Hospitals
  • 8.4 Homecare
  • 8.5 Other End Users

9 Global Psychedelic Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Johnson & Johnson (J&J)
  • 11.2 Enveric Biosciences
  • 11.3 Ceruvia Lifesciences
  • 11.4 Apex Labs
  • 11.5 Numinus Wellness Inc
  • 11.6 Jazz Pharmaceuticals
  • 11.7 Cybin Inc
  • 11.8 Revive Therapeutics
  • 11.9 Psychedelic Water
  • 11.10 PharmaTher Holdings Limited
  • 11.11 MindMed
  • 11.12 Compass Pathways
  • 11.13 Field Trip Health
  • 11.14 ATAI Life Sciences
  • 11.15 Hikma Pharmaceuticals PLC
  • 11.16 Verrian
  • 11.17 Celon Pharma SA
  • 11.18 NRX Pharmaceuticals
  • 11.19 Rose Hill Company
  • 11.20 Psycheceutical Bioscience Inc

List of Tables

  • Table 1 Global Psychedelic Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Psychedelic Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Psychedelic Market Outlook, By Lysergic Acid Diethylamide (LSD) (2021-2030) ($MN)
  • Table 4 Global Psychedelic Market Outlook, By 3,4-MethylEnedioxyMethamphetamine (Ecstasy) (2021-2030) ($MN)
  • Table 5 Global Psychedelic Market Outlook, By Phencyclidine (2021-2030) ($MN)
  • Table 6 Global Psychedelic Market Outlook, By Gamma Hydroxybutyric Acid (GHB) (2021-2030) ($MN)
  • Table 7 Global Psychedelic Market Outlook, By Etamine (2021-2030) ($MN)
  • Table 8 Global Psychedelic Market Outlook, By Ayahuasca (2021-2030) ($MN)
  • Table 9 Global Psychedelic Market Outlook, By Salvia (2021-2030) ($MN)
  • Table 10 Global Psychedelic Market Outlook, By Psilocybin (2021-2030) ($MN)
  • Table 11 Global Psychedelic Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 12 Global Psychedelic Market Outlook, By Injectable Psychedelic Drugs (2021-2030) ($MN)
  • Table 13 Global Psychedelic Market Outlook, By Oral Psychedelic Drugs (2021-2030) ($MN)
  • Table 14 Global Psychedelic Market Outlook, By Transdermal Psychedelic Drugs (2021-2030) ($MN)
  • Table 15 Global Psychedelic Market Outlook, By Rectal Psychedelic Drugs (2021-2030) ($MN)
  • Table 16 Global Psychedelic Market Outlook, By Nasal Psychedelic Drugs (2021-2030) ($MN)
  • Table 17 Global Psychedelic Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Psychedelic Market Outlook, By Major Depressive Disorder (2021-2030) ($MN)
  • Table 19 Global Psychedelic Market Outlook, By Resistant Depression (2021-2030) ($MN)
  • Table 20 Global Psychedelic Market Outlook, By Panic Disorder (2021-2030) ($MN)
  • Table 21 Global Psychedelic Market Outlook, By Post-Traumatic Stress Disorder (2021-2030) ($MN)
  • Table 22 Global Psychedelic Market Outlook, By Opiate Addiction (2021-2030) ($MN)
  • Table 23 Global Psychedelic Market Outlook, By Narcolepsy (2021-2030) ($MN)
  • Table 24 Global Psychedelic Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Psychedelic Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Psychedelic Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 27 Global Psychedelic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Psychedelic Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 29 Global Psychedelic Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.